Teleflex Inc.

Teleflex is a provider of medical technology products. The company primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. The company has seven reportable segments: Vascular North America; Interventional North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa; Asia; and Original Equipment Manufacturer and Development Services (OEM). The company's OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers.
  • TickerTFX
  • ISINUS8793691069
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

Moody's announces completion of a periodic review of ratings of Teleflex Incorporated

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Teleflex Incorporated. Global Credit Research- 27 Jun 2019. New York, June 27, 2019-- Moody's Investors Service has completed a periodic review of the ratings of Teleflex Incorporated and other ratings that are associated with the same analytical unit.

Moody's announces completion of a periodic review of ratings of Teleflex Incorporated

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Teleflex Incorporated. Global Credit Research- 27 Jun 2019. New York, June 27, 2019-- Moody's Investors Service has completed a periodic review of the ratings of Teleflex Incorporated and other ratings that are associated with the same analytical unit.

Teleflex Incorporated - March 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Teleflex Incorporated - December 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Teleflex Incorporated - September 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Teleflex Incorporated: Update to credit analysis

Teleflex's credit profile is constrained by high leverage and moderate scale. It benefits from strong market position of some products and an international footprint.

Jake Strole

Morningstar | Teleflex Continues to Meet Lofty Expectations

The Teleflex story is one of constant change, from the firm’s 1943 founding as a manufacturer of components for WWII aircraft to the final divestment of its industrial businesses in 2011, and full transition into medical devices thereafter. Under the leadership of former CEO Benson Smith, the company completed its transition from industrial conglomerate to pure-play medical device manufacturer, with the core business focusing on vascular, surgery, and anesthesia end markets. The firm’s strategy has been effective in carving out niche markets in which to compete, and thus far has remained relat...

Jake Strole

Teleflex Continues to Meet Lofty Expectations

Teleflex's first-quarter results were consistent with our expectations on an underlying basis, but reported numbers fell slightly short due to stronger currency headwinds than we anticipated. Nevertheless, it appears the firm is well on its way to meeting our forecasts for the full year, and we'll likely raise our $196 per share fair value estimate for this no-moat name by a mid-single-digit percentage to account for the cash flows received since our last update. The firm posted constant currenc...

Jake Strole

Morningstar | First-Quarter Results Put Teleflex on Track to Meet Our 2019 Projections

Teleflex's first-quarter results were consistent with our expectations on an underlying basis, but reported numbers fell slightly short due to stronger currency headwinds than we anticipated. Nevertheless, it appears the firm is well on its way to meeting our forecasts for the full year, and we'll likely raise our $196 per share fair value estimate for this no-moat name by a mid-single-digit percentage to account for the cash flows received since our last update. The firm posted constant currency revenue growth of 7.6%, ahead of initial guidance that called for 6%-7% for the full year. Streng...

Jake Strole

First-Quarter Results Put Teleflex on Track to Meet Our 2019 Projections

Teleflex's first-quarter results were consistent with our expectations on an underlying basis, but reported numbers fell slightly short due to stronger currency headwinds than we anticipated. Nevertheless, it appears the firm is well on its way to meeting our forecasts for the full year, and we'll likely raise our $196 per share fair value estimate for this no-moat name by a mid-single-digit percentage to account for the cash flows received since our last update. The firm posted constant currenc...

Jake Strole

Morningstar | Teleflex's Recent Acquisitions Continue to Outperform Expectations

The Teleflex story is one of constant change, from the firm’s 1943 founding as a manufacturer of components for WWII aircraft to the final divestment of its industrial businesses in 2011, and full transition into medical devices thereafter. Under the leadership of former CEO Benson Smith, the company completed its transition from industrial conglomerate to pure-play medical device manufacturer, with the core business focusing on vascular, surgery, and anesthesia end markets. The firm’s strategy has been effective in carving out niche markets in which to compete, and thus far has remained relat...

1 director bought

A director at Teleflex Inc bought 1,250 shares at 285.000USD and the significance rating of the trade was 88/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board...

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

ValuEngine Rating and Forecast Report for TFX

MarketLine Department

Boston Scientific Corporation - Strategy, SWOT and Corporate Finance Report

Summary Boston Scientific Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Boston Scientific Corporation (Boston Scientific) is a manufacturer of medical devices used in interventional medical specialties. The company’s solutions include drug-eluting coronary stent systems, percutaneous coronary interventions (PCI), intravascular catheter-directed ult...

MarketLine Department

Smiths Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Smiths Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Smiths Group plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key H...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A few Consumer Discretionary names continue to act well. The list is thinning of attractive names though. (ex. FOXF, UEIC, DECK, CHDN, WING, YUM, BOOT, RCI, POOL, DLTR, and AAN) • A number of Health Care Sector names are attractive. (ex. MASI, TFX, CNMD, STE, CRVL, LNTH, HAE, COO, WST, RGEN, ANIK, NEO, and TECH) • Attractive Technology and Services names include: MANH, CDNS, ANSS, AGYS, TTEC, CLGX, MMS, and KBR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch